Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cardfail.2025.04.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Amyloid-specific medication in transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis of cardiovascular outcome trials.
J Card Fail
August 2025
Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria. Electronic address:
Background: Introduction of disease-specific medication has revolutionized the management of transthyretin associated cardiomyopathy (ATTR-CM). However, dedicated trials included different patient populations, primary endpoints, and follow-up periods, rendering study comparison challenging. This systematic review and meta-analysis aimed to harmonize data from all phase-3 placebo-controlled drug trials in ATTR-CM to inform on the magnitude and timing of treatment efficacy of ATTR-specific medication.
View Article and Find Full Text PDFWild-type transthyretin cardiac amyloidosis: a case of multisystemic involvement and review of literature.
Rom J Morphol Embryol
August 2025
Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Romania;
Introduction: Cardiac amyloidosis (CA) represents a progressively evolving infiltrative pathology, defined by the myocardial accumulation of amyloid fibrils. The condition predominantly originates from transthyretin-derived (ATTR) or immunoglobulin light chain-related (AL) amyloidosis. ATTR cardiomyopathy (ATTR-CM), particularly the wild-type (wt) form (wtATTR-CM), is becoming more widely acknowledged as a contributor to cardiac dysfunction in the elderly population.
View Article and Find Full Text PDFImpact of a Checklist-Based Strategy for Cardiac Amyloidosis Screening on Diagnosis Rates in Heart Failure Patients (CHECKAMIC Study).
Eur J Intern Med
August 2025
Internal Medicine Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain; Department of Medicine and Medical Specialties, Facultad de Medicina y Ciencias de la Salud, Universidad de Alcalá, IRYCIS, Madrid, Spain.
Background: Transthyretin-associated cardiac amyloidosis (ATTR-CM) is an underdiagnosed cause of heart failure (HF), particularly in elderly patients. Delayed diagnosis limits access to emerging disease-modifying therapies. We aimed to evaluate the impact of implementing a checklist-based screening strategy for ATTR-CM in specialized HF units.
View Article and Find Full Text PDFSuccessful Heart and Kidney Transplant in End-Stage Wild-Type TTR Amyloidosis and Renal Failure.
JACC Case Rep
August 2025
Department of Cardiovascular Disease, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Florida, Weston, Florida, USA. Electronic address:
Background: End-stage heart failure secondary to transthyretin cardiac amyloidosis (ATTR-CM) has a poor prognosis, particularly when complicated by multiorgan involvement such as renal failure. Combined heart and kidney transplantation remains a viable therapeutic option in carefully selected patients.
Case Summary: A 73-year-old man recently diagnosed with ATTR-CM via technetium-99m pyrophosphate scintigraphy presented in multiorgan shock.
Real-World Clinical Evidence With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy - A Contemporary Review.
Circ Rep
August 2025
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University Kumamoto Japan.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly recognized as a cause of heart failure with preserved ejection fraction in older adults. Tafamidis, a transthyretin stabilizer, is the first disease-modifying therapy approved for ATTR-CM. Although its efficacy was demonstrated in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) trial, real-world data are essential to evaluate its effectiveness across broader and more diverse patient populations.
View Article and Find Full Text PDF